# A Clinical Trial to Evaluate the Reversibility of Abacavir/Lamivudine/Dolutegravir CNS-Related Neurotoxicity After Switching to Tenofovir/Alafenamide/Emtricitabine/Darunavir/Cobicistat (TAF/FTC/DRV/c)

> **NCT03685500** · PHASE4 · COMPLETED · sponsor: **Fundacion SEIMC-GESIDA** · enrollment: 78 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Symtuza® (TAF/FTC/DRV/c)
- **DRUG:** ABC/3TC/DTG + Symtuza® (TAF/FTC/DRV/c)

## Key facts

- **NCT ID:** NCT03685500
- **Lead sponsor:** Fundacion SEIMC-GESIDA
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-04
- **Primary completion:** 2020-06-25
- **Final completion:** 2020-06-25
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2022-06-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03685500

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03685500, "A Clinical Trial to Evaluate the Reversibility of Abacavir/Lamivudine/Dolutegravir CNS-Related Neurotoxicity After Switching to Tenofovir/Alafenamide/Emtricitabine/Darunavir/Cobicistat (TAF/FTC/DRV/c)". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT03685500. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*